Co-treating opioid and alcohol use disorders in the United States, 1960–2026: A historical policy review in the glucagon-like peptide-1 (GLP-1) era
Fares Qeadan, William A Barbeau · 2026
Read Co-treating opioid and alcohol use disorders in the United States, 1960–2026: A historical policy review in the glucagon-like peptide-1 (GLP-1) era by Fares Qeadan, William A Barbeau (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13578398.txt.
Description
Fares Qeadan and William Barbeau review six decades of US policy on dual addiction in a 2026 paper. Opioid and alcohol disorders often travel together, yet care long treated them apart. The review spans methadone's rise in the nineteen sixties to today's metabolic drugs. Four eras structure the story.
Early care split substances into silos. Federal programs then medicalized opioid care under tight rules. Parity laws and health reform later pushed joint treatment, unevenly. Now GLP-1 drugs hint at a shared metabolic lever, still unproven for addiction. Rules and payment, the authors stress, shaped access as much as science did. Fair, integrated care remains the unfinished task.
Catalog record
| CREATOR | Fares Qeadan, William A Barbeau |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |